GILD Stock Chart & Fundamental Analysis

Interactive Chart

About Gilead Sciences, Inc.

Name

Gilead Sciences, Inc.

CEO

Daniel O'Day

Website

www.gilead.com

Industry

Healthcare

Year Founded

1987

Employees

17,600

Gilead Sciences, Inc. is a biopharmaceutical company focused on antiviral and immunology therapies that are used by health systems around the world. The portfolio spans treatments for infectious diseases and serious chronic conditions, with programs that move from discovery to access through a single, repeatable pathway. Research groups work with clinical partners to translate science into medicines that can be delivered at scale, while medical affairs teams support appropriate use in real settings. Manufacturing and quality systems favor reliability over showy launches, so supply stays steady as demand shifts between regions. The company operates across the Americas, Europe, and Asia with a consistent emphasis on safety, evidence, and responsible distribution. In coverage of large-cap biotech, Gilead Sciences, Inc. stock (GILD) often marks investor interest in therapeutic franchises that combine established use with ongoing research.

Analyst Ratings

Consensus Recommendation

Buy8

Hold11

Sell4

Fundamentals & Financials

Revenue (TTM)

$29.4B

Net Income (TTM)

$8.5B

EPS (TTM)

$6.85

ROA (TTM)

14.42%

Current Ratio

1.68

Dividend Yield

0.097%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q4 2025	Q3 2025	Q2 2025
Revenue	$7,925M	$7,769M	$7,081M
Cost of Sales	$1,043M	$1,569M	$1,501M
Gross Profit	$6,882M	$6,200M	$5,580M
Operating Income	$2,964M	$3,327M	$2,474M
Net Income	$2,183M	$3,052M	$1,960M
EPS	$1.76	$2.46	$1.57

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

Gilead Sciences, Inc.'s Technical Indicators Summary

GILD shows a neutral technical profile as short-term momentum registers modest strength while broader momentum indicators sit near neutral. Trend strength is subdued with ADX below 20, and the stock trades around its short EMAs but beneath several medium-term moving averages even though the 200-day average remains well below price. Volatility is moderate and unchanged, and on-balance volume reads constructive, suggesting buying has been steady despite mixed price signals. The classic pivot near 139.90 is close to current levels, underscoring the lack of directional conviction. Technical takeaway: Neutral.

Buy

8 signals

Neutral

11 signals

Sell

4 signals

Overall: Neutral48% Neutral signals

Indicator	Value	Signal	Explanation
RSI (14)	47.41	Neutral	RSI (47.41) is neutral.
Stochastic %K (14, 3, 3)	46.27	Neutral	Stochastic (46.27) is neutral.
CCI (20)	-25.59	Neutral	CCI (-25.59) is neutral.
WPR (14)	-51.33	Neutral	Williams %R (-51.33) is neutral.
Momentum (10)	2.92	Buy	Momentum (2.92) is positive.
MFI	35.43	Neutral	MFI (35.43) is neutral.
MACD Level (12, 26)	-1.61	Neutral	Potential bullish reversal: MACD (-1.61) crossed above signal but is still negative.
Bollinger Bands	$132.98 - $149.15	Neutral	Price is within the bands.
ATR (14)	$3.20 (2.28%)	Neutral	Moderate Volatility (2.28%).
ADX (14)	17.73	Neutral	Weak or consolidating trend (ADX < 25). ADX(17.73), +DI(21.12), -DI(23.39)
OBV	145,383,136	Buy	Bullish volume pressure: OBV is above its 20-day SMA. OBV(145,383,136), 20D-SMA-OBV(141,897,627)
Classic Pivot Point	$139.90	Neutral	Price ($140.13) hovering around equilibrium (P: $139.90) — no clear directional bias.
Fibonacci Pivot Point	$139.90	Neutral	Price ($140.13) hovering around equilibrium (P: $139.90) — no clear directional bias.
Simple Moving Averages	$124.40 - $144.72(5 indicators)	Buy	SMA group: 3/5 bullish, 2 bearish, 0 neutral. Price above key SMA averages.
Exponential Moving Averages	$126.36 - $140.64(5 indicators)	Buy	EMA group: 3/5 bullish, 2 bearish, 0 neutral. Price above key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

By the close, GILD remained slightly above yesterday’s 139.71, with a small 0.30% gap leaving it around 140.13. End-of-day, the peer group was roughly unchanged (-0.37%), limiting broader influence on GILD. GILD edges higher as peers hold steady, with muted sector moves limiting broader influence.

Price Change

from $140.13 close

+$0.01

Trading Volume

Below avg (6.9M)

vs S&P 500 Today

Inline with Market

+0.04%

52-Week Position

Upper range

73.2%

Updated: April 6, 2026 at 20:01 UTC